Effects of EPs 7630 on the duration of inability to work in acute bronchitis – a meta-analysis
Keywords:
Pelargonium, EPs 7630, acute bronchitis, adults, inability to work, meta-analysisAbstract
Background: Acute bronchitis (AB) has an enormous economic impact through lost working time. We investigated whether treatment with Pelargonium extract EPs 7630 may reduce the time of inability to work.
Methods: A meta-analysis of double-blind, randomized, placebo-controlled trials with adult patients suffering from AB was performed. The average number of days of inability to work and the proportion of patients who were still unable to work after one week’s treatment were assessed.
Results: Four clinical trials with a total of 1,011 evaluable patients who received the marketed dosage of EPs 7630 (n=505) or placebo (n=506) for seven days were included in the meta-analysis. At baseline, 845/1,011 patients (83.6%) were unable to work. In the four trials, the proportion decreased to between 19 and 14% for EPs 7630 and to between 41 and 55% for placebo (meta-analysis risk ratio and 95% confidence interval: 0.35; 0.26-0.45; p<0.001). For the number of sick days, a weighted mean difference of 1.73 days (1.17-2.29 days; p<0.001) favoring EPs 7630 was observed.
Conclusions: For adults suffering from AB, this meta-analysis demonstrates that seven days’ treatment with Pelargonium sidoides extract EPs 7630 significantly reduces the average number of sick days and significantly increases the proportion of patients who are able to return to work.
References
Kinkade S, Long NA. Acute bronchitis. Am Fam Physician 2016;94:560-5.
Tanner M, Karen Roddis J. Antibiotics for acute bronchitis. Nurs Stand 2018;32:41-3.
National Center for Health Statistics CfDCaP. National hospital ambulatory medical care survey: 2011 outpatient department summary tables. Available from: https://www.cdc.gov/nchs/data/ahcd/nhamcs_outpatient/2011_opd_web_tables.pdf
Braman SS. Chronic cough due to acute bronchitis: ACCP evidence-based clinical practice guidelines. Chest 2006;129:95S-103S.
Verheij T, Hermans J, Kaptein A, Mulder J. Acute bronchitis: Course of symptoms and restrictions in patients' daily activities. Scand J Prim Health Care 1995;13:8-12.
Godycki-Cwirko M, Nocun M, Butler CC, Little P, Verheij T, Hood K, et al. Family practitioners' advice about taking time off work for lower respiratory tract infections: A prospective study in twelve European primary care networks. PLoS One 2016;11:e0164779.
Hordijk PM, Broekhuizen BDL, Butler CC, Coenen S, Godycki-Cwirko M, Goossens H, et al. Illness perception and related behaviour in lower respiratory tract infections - a European study. Fam Pract 2015;32:152-8.
Birnbaum HG, Morley M, Greenberg PE, Colice GL. Economic burden of respiratory infections in an employed population. Chest 2002;122:603-11.
Birnbaum H, Morley M, Leong S, Greenberg P, Colice G. Lower respiratory tract infections: Impact on the workplace. PharmacoEconomics 2003;21:749-59.
Smith SM, Fahey T, Smucny J, Becker LA. Antibiotics for acute bronchitis. Cochrane Database Syst Rev 2017;6:CD000245.
Holzinger F, Beck S, Dini L, Stoter C, Heintze C. The diagnosis and treatment of acute cough in adults. Dtsch Arztebl Int 2014;111:356-63.
Arroll B. Common cold. BMJ Clin Evid 2011;03:1510.
Witte K, Koch E, Volk H-D, Wolk K, Sabat R. The Pelargonium sidoides extract EPs 7630 drives the innate immune defense by activating selected map kinase pathways in human monocytes. PLoS One 2015;10:e0138075.
Kolodziej H, Kayser O, Radtke OA, Kiderlen AF, Koch E. Pharmacological profile of extracts of Pelargonium sidoides and their constituents. Phytomedicine 2003;10:S18-24.
Witte K, Koch E, Volk H-D, Wolk K, Sabat R. The herbal extract EPs® 7630 increases the antimicrobial airway defense through monocyte-dependent induction of IL-22 in T cells. J Mol Med (Berl) 2020;98:1493-503.
Bao Y, Gao Y, Koch E, Pan X, Jin Y, Cui X. Evaluation of pharmacodynamic activities of EPs® 7630, a special extract from roots of Pelargonium sidoides, in animals models of cough, secretolytic activity and acute bronchitis. Phytomedicine 2015;22:504-9.
Michaelis M, Doerr HW, Cinatl J, Jr. Investigation of the influence of EPs® 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses. Phytomedicine 2011;18:384-6.
Roth M, Fang L, Stolz D, Tamm M. Pelargonium sidoides radix extract EPs 7630 reduces rhinovirus infection through modulation of viral binding proteins on human bronchial epithelial cells. PLoS One 2019;14:e0210702.
Roth M, Sun Q, Tamm M. Up-regulated vitamin D receptor by Pelargonium sidoides extract EPs® 7630 contributes to rhinovirus defense in bronchial epithelial cells. Pharmaceuticals (Basel) 2021;14:172.
Papies J, Emanuel J, Heinemann N, Kulić Ž, Schroeder S, Tenner B, et al. Antiviral and immunomodulatory effects of Pelargonium sidoides DC. root extract EPs® 7630 in SARS-CoV-2-infected human lung cells. Front Pharmacol 2021;12:757666.
Papies J, Emanuel J, Heinemann N, Kulić Ž, Schroeder S, Tenner B, et al. Corrigendum: Antiviral and immunomodulatory effects of Pelargonium sidoides DC. root extract EPs® 7630 in SARS-CoV-2-infected human lung cells. Front Pharmacol 2021;12:814452.
Alossaimi MA, Alzeer MA, Abdel Bar FM, ElNaggar MH. Pelargonium sidoides root extract: Simultaneous HPLC separation, determination, and validation of selected biomolecules and evaluation of SARS-CoV-2 inhibitory activity. Pharmaceuticals (Basel) 2022;15:1184.
Moyo M, Van Staden J. Medicinal properties and conservation of Pelargonium sidoides DC. J Ethnopharmacol 2014;152:243-55.
Careddu D, Pettenazzo A. Pelargonium sidoides extract EPs 7630: A review of its clinical efficacy and safety for treating acute respiratory tract infections in children. Int J Gen Med 2018;11:91-8.
Agbabiaka TB, Guo R, Ernst E. Pelargonium sidoides for acute bronchitis: A systematic review and meta-analysis. Phytomedicine 2008;15:378-85.
Timmer A, Günther J, Motschall E, Rücker G, Antes G, Kern WV. Pelargonium sidoides extract for treating acute respiratory tract infections. Cochrane Database Syst Rev 2013;3:CD006323.
Ulbricht C, Abrams TR, Conquer J, Costa D, Serrano JM, Iovin R, et al. An evidence-based systematic review of umckaloabo (Pelargonium sidoides) by the natural standard research collaboration. J Diet Suppl 2010;7:283-302.
Matthys H, Köhler S, Kamin W. Safety and tolerability of EPs 7630 in clinical trials. Adv Pharmacoepidemiol Drug Saf 2013;2:142.
Matthys H, Lehmacher W, Zimmermann A, Brandes J, Kamin W. EPs 7630 in acute respiratory tract infections – a systematic review and meta-analysis of randomized clinical trials. J Lung Pulm Respir Res 2016;3:4-15.
Kamin W, Lehmacher W, Zimmermann A, Brandes-Schramm J, Funk P, Seifert GJ, et al. Treatment of sore throat and hoarseness with Pelargonium sidoides extract EPs 7630: A meta-analysis. Pharmadvances 2022;4:88-103.
Kardos P, Lehrl S, Kamin W, Matthys H. Assessment of the effect of pharmacotherapy in common cold/acute bronchitis - the bronchitis severity scale (BSS). Pneumologie 2014;68:542-6.
Lehrl S, Matthys H, Kamin W, Kardos P. The BSS - a valid clinical instrument to measure the severity of acute bronchitis. J Lung Pulm Respir Res 2014;1:72-80.
Seifert G, Brandes-Schramm J, Zimmermann A, Lehmacher W, Kamin W. Faster recovery and reduced paracetamol use - a meta-analysis of EPs 7630 in children with acute respiratory tract infections. BMC Pediatr 2019;19:119.
Keck T, Strobl A, Weinhaeusel A, Funk P, Michaelis M. Pelargonium extract EPs 7630 in the treatment of human corona virus-associated acute respiratory tract infections – a secondary subgroup-analysis of an open-label, uncontrolled clinical trial. Front Pharmacol 2021;12:666546.
Matthys H, Eisebitt R, Seith B, Heger M. Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomised, double-blind, placebo-controlled trial. Phytomedicine 2003;1:S7-17.
Matthys H, Heger M. Treatment of acute bronchitis with a liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): A randomised, double-blind, placebo-controlled, multicentre study. Curr Med Res Opin 2007;23:323-31.
The Cochrane Collaboration. Cochrane RevMan - Review Manager (RevMan), version 5.3 [computer program]. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
Matthys H, Funk P. EPs 7630 improves acute bronchitic symptoms and shortens time to remission. Results of a randomised, double-blind, placebo-controlled, multicentre trial. Planta Med 2008;74:686-92.
Matthys H, Lizogub VG, Funk P, Malek FA. [Pelargonium sidoides bei akuter Bronchitis - gesundheitsbezogene Lebensqualität und Therapiebeurteilung aus Patientensicht unter Behandlung mit EPs 7630].[Article in German]. Wien Med Wochenschr 2010;160:564-70.
Kamin W, Funk P, Seifert G, Zimmermann A, Lehmacher W. EPs 7630 is effective and safe in children under 6 years with acute respiratory tract infections: Clinical studies revisited. Curr Med Res Opin 2018;34:475-85.
Timmer A, Günther J, Rücker G, Motschall E, Antes G, Kern WV. Pelargonium sidoides extract for acute respiratory tract infections. Cochrane Database Syst Rev 2008;3:CD006323.
Wopker PM, Schwermer M, Sommer S, Längler A, Fetz K, Ostermann T, et al. Complementary and alternative medicine in the treatment of acute bronchitis in children: A systematic review. Complement Ther Med 2020;49:102217.
Kamin W, Maydannik V, Malek FA, Kieser M. Efficacy and tolerability of EPs 7630 in children and adolescents with acute bronchitis - a randomized, double-blind, placebo-controlled multicenter trial with a herbal drug preparation from Pelargonium sidoides roots. Int J Clin Pharmacol Ther 2010;48:184-91.
Kamin W, Maydannik VG, Malek FA, Kieser M. Efficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis - a randomized, double-blind, placebo-controlled clinical dose-finding study. Acta Paediatr 2010;99:537-43.
Kamin W, Ilyenko LI, Malek FA, Kieser M. Treatment of acute bronchitis with EPs 7630: Randomized, controlled trial in children and adolescents. Pediatr Int 2012;54:219-26.
Riley DS, Lizogub VG, Heger M, Funk P, Mueller H, Lehmacher W. Treatment with EPs 7630, a Pelargonium sidoides root extract, is effective and safe in patients with the common cold: Results from a randomized, double blind, placebo-controlled clinical trial. Integr Med (Encinitas) 2019;18:42-51.
Matthys H, Heger M. EPs® 7630-solution - an effective therapeutic option in acute and exacerbating bronchitis. Phytomedicine 2007;14:S65-8.
Anonymous. Das Übel mit der Wurzel packen - Zulu-Medizin bessert Husten, Halsweh und Schnupfen. MMW Fortsch Med 2003;145:56.
Matthys H, Kamin W. Positioning of the Bronchitis Severity Score (BSS) for standardised use in clinical studies. Curr Med Res Opin 2013;29:1383-90.
Whitehead A, Simpson C, Willcox M, Webley F, Hay AD, Butler C, et al. Hatric: A study of Pelargonium sidoides root extract EPs® 7630 (Kaloba®) for the treatment of acute cough due to lower respiratory tract infection in adults-study protocol for a double blind, placebo-controlled randomised feasibility trial. Pilot Feasibility Stud 2019;5:98.
Matthys H, Lizogub VG, Malek FA, Kieser M. Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: A randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides. Curr Med Res Opin 2010;26:1413-22.
Chuchalin AG, Berman B, Lehmacher W. Treatment of acute bronchitis in adults with a Pelargonium sidoides preparation (EPs® 7630): A randomized, double-blind, placebo-controlled trial. Explore (NY) 2005;1:437-45.
Martin D, Konrad M, Adarkwah CC, Kostev K. Reduced antibiotic use after initial treatment of acute respiratory infections with phytopharmaceuticals- a retrospective cohort study. Postgrad Med 2020;132:412-8.
The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions, version 5.1.0 (updated March 2011). Available from https://handbook-5-1.cochrane.org/
Published
Issue
Section
License
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Mattioli 1885 has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
How to Cite
